source
- Arcus kidney cancer drug shows stronger potency than Merck's Welireg, boosting sharesArcus Biosciences reported follow‑up data from its late‑stage kidney cancer trial that suggest its experimental therapy, casdatifan, may be more potent than Merck's approved drug Welireg. Analysts…
- Astellas partners with AI Proteins on $400M computational drug discovery dealAstellas Pharma of Japan has entered a partnership with Boston based AI Proteins to apply its computational design platform to drug discovery. AI Proteins builds miniproteins from scratch using ar…